Abstracts tagged "Morbidity and mortality and systemic lupus erythematosus (SLE)"

Abstract Number: 298 • 2018 ACR/ARHP Annual Meeting
Factors Affecting Inpatient Mortality in Hospitalizations for Sepsis with Underlying Systemic Lupus Erythematosus: Data from the National Inpatient Sample 2010-2014
Karan Chugh¹, Karan Jatwani², Jasleen Kaur³ and Shraddha Jatwani⁴, ¹Division of Pulmonary, Critical Care & Sleep, Wayne State University/Detroit Medical Center, Detroit, MI, ²Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital, New York, NY, ³Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI, ⁴Department of Internal Medicine, Division of Rheumatology, Henry Ford Allegiance Health, Jackson, MI
Background/Purpose: Infections are associated with significant morbidity and mortality in systemic lupus erythematosus (SLE). Clinical outcomes of SLE patients hospitalized is variable due to variable…
Abstract Number: 1873 • 2018 ACR/ARHP Annual Meeting
Age- and Cause-Specific Standardized Mortality Ratio of Systemic Lupus Erythematosus Patients in Ontario, Canada over 43 Years (1971-2013)
Konstantinos Tselios, Dafna D Gladman, Barry Sheane, Jiandong Su and Murray Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The major causes of early death in systemic lupus erythematosus (SLE) include active disease and infections, while cardiovascular complications and malignancies dominate the late…
Abstract Number: 2896 • 2018 ACR/ARHP Annual Meeting
Increased Mortality Among Patients with Systemic Lupus Erythematosus after Hydroxychloroquine Discontinuation
April Jorge¹, Na Lu^2,3, Eric C. Sayre³, Hamid Tavakoli⁴, Natalie McCormick⁵, John M. Esdaile^3,6, Mary DeVera⁵, Hyon K. Choi¹ and J. Antonio Avina-Zubieta⁷, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁶Department of Medicine, Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁷Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE. Use of this medication has previously been associated with a substantial survival benefit among SLE…
Abstract Number: 1610 • 2017 ACR/ARHP Annual Meeting
The Impact of Alcohol Use on Cardiovascular Events and Overall Mortality in Women with Systemic Lupus Erythematosus
April Jorge¹, Leo Lu², Yuqing Zhang³, Sharan K. Rai⁴ and Hyon K. Choi⁴, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Women with SLE have an increased risk of cardiovascular disease (CVD) and premature death. In the general population, moderate alcohol intake is associated with…
Abstract Number: 3051 • 2016 ACR/ARHP Annual Meeting
Is Frailty a Relevant Concept in Systemic Lupus Erythematosus (SLE)?
Patricia P. Katz¹, James Andrews², Edward H. Yelin¹ and Jinoos Yazdany¹, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Frailty, a syndrome of weight loss, weakness, slowness, exhaustion, and inactivity, has been examined primarily in geriatric cohorts and is associated with poor health…
Abstract Number: 1811 • 2016 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus: Detailed Anatomy of a Cohort (follow-up for more than 35 years).
Borja Del Carmelo Gracio Tello¹, Alexis Jones¹, Charles Raine¹ and David Isenberg², ¹Rheumatology, University College Hospital, London, London, United Kingdom, ²University College Hospital, London, London, United Kingdom
Background/Purpose: Very long-term follow-up has rarely been reported in lupus patients. We report on the follow up of (up to 37 years) of our lupus…
Abstract Number: 60 • 2015 ACR/ARHP Annual Meeting
Mortality of Systemic Lupus Erythematosus in Puerto Rico Assessed By Multiple-Cause-of-Death Analysis
Mariangelí Arroyo-Ávila¹, José G. Conde² and Luis M. Vilá¹, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²School of Medicine and Research Centers in Minority Institutions Program, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that is associated with a high morbidity and mortality. The specific causes of death vary…
Abstract Number: 734 • 2015 ACR/ARHP Annual Meeting
Disease Patterns, Flare Incidence and Organ Damage Among Filipino Patients with Systemic Lupus Erythematosus: a One-Year Observational Study
Mary Flor Joy Edar, Leonid Zamora, Catherine Macapagal and Sandra V. Navarra, Rheumatology, University of Santo Tomas Hospital, Manila, Philippines
Background/Purpose: This study describes the disease patterns, flare incidence, hospitalizations and causes of mortality in a cohort of Filipino patients with systemic lupus erythematosus (SLE),…
Abstract Number: 2899 • 2015 ACR/ARHP Annual Meeting
Mortality Related to Pediatric Systemic Lupus Erythematosus: A Multiple Cause-of-Death Analysis in France
laurent chiche¹, sarah malaekah², alexandre belot³, Brigitte Bader-Meunier⁴, gregoire rey⁵, Noémie Jourde-Chiche Sr.⁶ and mireille eb⁵, ¹internal medicine, Hopital Europeen, Marseille, France, ²pediatry, CHU Lyon, Lyon, France, ³Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵cepidc, paris, France, ⁶Nephrology, Aix-Marseille Université - APHM, Marseille, France
Background/Purpose: Although regarded as a disease of adulthood, SLE is also seen in children, and is associated with an increased risk for aggressive clinical course…
Abstract Number: 1855 • 2014 ACR/ARHP Annual Meeting
Not Keeping up with the Times: High Mortality and Early Death Due to Disease in North American Natives with Systemic Lupus Erythematosus (SLE)
Ripneet Puar¹, Carol A. Hitchon², David B. Robinson³, Hani El-Gabalawy³, Navjot Dhindsa¹ and Christine A. Peschken⁴, ¹Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba, Canada, Winnipeg, MB, Canada
Background/Purpose: Reports in recent decades show drastic improvements in survival of SLE patients, with 10-15 year survival rates of >90%. However, little is known about…
Abstract Number: 1081 • 2014 ACR/ARHP Annual Meeting
Prediction of Mortality Risk Related to Cerebrovascular Accidents in Patients with Systemic Lupus Erythematosus (SLE) vs Anti-Phospho-Lipid-Antibody (aPL) syndrome
Khushboo Sheth¹, Tapan Mehta², Sonam Puri¹, Ronak Soni³ and Kathan Mehta⁴, ¹Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, ²Neurology, University of Connecticut, Farmington, CT, Farmington, CT, ³Internal Medicine, Government Medical College, Surat, India, ⁴Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, Pittsburgh, PA
Background/Purpose : It is well-established that patients with co-existent Systemic Lupus Erythematosus (SLE) and Anti-Phospho-Lipid-Antibody (aPL) syndrome are at increased risk of cerebrovascular accidents (CVA).…
Abstract Number: 616 • 2013 ACR/ARHP Annual Meeting
Trends Of Mortality Associated To Systemic Lupus Erythematosus At The Nation Level: A Multiple Cause-Of-Death Analysis In France
Laurent Chiche Sr.¹, Guillemette Thomas², Albetine Aouba³, Julien Mancini⁴, Gabrielle Sarlon⁵, Noémie Jourde⁶, Eric Jougla³ and Jean-Robert Harle², ¹Internal Medicine, CHU Marseille, Marseille, France, ²Internal Medicine, APHM, Marseille, France, ³inserm CépiDc, paris, France, ⁴public health, APHM, Marseille, France, ⁵APHM, marseille, France, ⁶APHM, Marseille, France
Background/Purpose: The overall mortality rate of Systemic Lupus Erythematosus (SLE) has improved significantly over the past 50 years but is still high as compared with…
Abstract Number: 2686 • 2012 ACR/ARHP Annual Meeting
Difference in Clinical Features and Mortality Between Pediatric-Onset and Adult-Onset Systemic Lupus Erythematosus
So-Yeon Park¹, Jeeseon Shim², Dam Kim³, Ji-Young Choi³, So-Young Bang⁴, Chan-Bum Choi⁵ and Sang-Cheol Bae⁶, ¹Department of rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ⁵Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: The aim of this study was to investigate differences in clinical features and outcomes including mortality between pediatric-onset systematic lupus erythematosus (pSLE) and adult-onset…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].